Alterations in human papillomavirus-related biomarkers after treatment of cervical intraepithelial neoplasia

Valasoulis, George; Koliopoulos, George; Founta, Christina; Kyrgiou, Maria; Tsoumpou, Ioanna; Valari, Olga; Martin-Hirsch, P; Daponte, Alexandros; Karakitsos, Petros; Paraskevaidis, Evangelos

doi:10.1016/j.ygyno.2010.12.003

Cited by 29 publications

(29 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So far CLART’s clinical performance has only been evaluated in a handful of studies, and several of these did not compare with that of HC2 [8, 13, 23–26]. In 405 Portuguese women aged 25-63 years attending colposcopy for cervical abnormalities, 268 (63%) tested positive on CLART (13 high-risk genotypes), and 274 (64%) tested positive on HC2.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system

et al. 2014

View full text Add to dashboard Cite

BackgroundHuman papillomavirus (HPV) genotyping assays are becoming increasingly attractive for use in mass screening, as they offer a possibility to integrate HPV screening with HPV vaccine monitoring, thereby generating a synergy between the two main modes of cervical cancer prevention. The Genomica CLART HPV2 assay is a semi-automated PCR-based microarray assay detecting 35 high-risk and low-risk HPV genotypes. However, few reports have described this assay in cervical screening.An aim of the present study, Horizon, was to assess the prevalence of high-risk HPV infections in Copenhagen, Denmark, an area with a high background risk of cervical cancer where women aged 23-65 years are targeted for organized screening.MethodsMaterial from 5,068 SurePath samples of women participating in routine screening and clinical follow-up of cervical abnormalities was tested using liquid based cytology, CLART HPV2 and Hybrid Capture 2 (HC2).ResultsAt least one of the 35 defined genotypes was detected by CLART in 1,896 (37%) samples. The most frequent high-risk genotypes were HPV 16 (7%), HPV 52 (5%), and HPV 31 (4%). The most frequent low-risk genotypes were HPV 53 (5%), HPV 61 (4%), and HPV 66 (3%). Among 4,793 women targeted by the screening program (23-65 years), 1,166 (24%) tested positive for one or more of the 13 high-risk genotypes. This proportion decreased from 40% at age 23-29 years to 10% at age 60-65 years. On HC2, 1,035 (20%) samples were positive for any high-risk and thus CLART showed a higher analytical sensitivity for 13 high-risk HPV genotypes than HC2, and this was found in all age-groups and in women normal cytology.ConclusionsCLART performed well with a positive reproducibility for high-risk genotypes of 86%, and a negative reproducibility of 97%. This report furthermore updates the genotype distribution in Denmark prior to the inclusion of the HPV-vaccinated cohorts into the screening program, and as such represents a valuable baseline for future vaccine impact assessment.Electronic supplementary materialThe online version of this article (doi:10.1186/1471-2334-14-413) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Earlier studies reported mixed results when the detection of HPV and cervical lesions by CLART was compared to that of HC2 [8–13]. All studies were undertaken using samples stored in PreservCyt, and experts have called for evaluation of HPV assays using other storage media [14], e.g.…”

Section: Introductionmentioning

confidence: 99%

HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system

et al. 2014

View full text Add to dashboard Cite

show abstract

“…HPV genotyping has been used to assess the impact of various factors on LSIL progression in follow-up cervical smears [63]. In our study, the lack of a significant correlation might be imputed to the small sample, as previously stated.…”

Section: Discussionmentioning

confidence: 68%

B-lymphocyte, Macrophage and Mast Cell Density in the Stroma Underlying HPV-Related Cervical Squamous Epithelial Lesions and their Relationship to Disease Severity: an Immunohistochemical Study

Foukas¹,

Zourla²,

Tsiodras³

et al. 2012

J Clinic Experiment Pathol

View full text Add to dashboard Cite

show abstract

“…A combination of the proposed HPV-related biomarkers as well as other epidemiological data, available from women's history, such as demographic characteristics, sexual behavior, and potential cofactor information (smoking, condom use, etc. ), in addition to cytology and colposcopy, could identify individual risk estimation for CIN2+, CIN3+ or even invasive disease [40, 44]. …”

Section: Resultsmentioning

confidence: 99%

Identification of Women for Referral to Colposcopy by Neural Networks: A Preliminary Study Based on LBC and Molecular Biomarkers

Karakitsos

Chrelias

Pouliakis

et al. 2012

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

Objective of this study is to investigate the potential of the learning vector quantizer neural network (LVQ-NN) classifier on various diagnostic variables used in the modern cytopathology laboratory and to build an algorithm that may facilitate the classification of individual cases. From all women included in the study, a liquid-based cytology sample was obtained; this was tested via HPV DNA test, E6/E7 HPV mRNA test, and p16 immunostaining. The data were classified by the LVQ-NN into two groups: CIN-2 or worse and CIN-1 or less. Half of the cases were used to train the LVQ-NN; the remaining cases (test set) were used for validation. Out of the 1258 cases, cytology identified correctly 72.90% of the CIN-2 or worst cases and 97.37% of the CIN-1 or less cases, with overall accuracy 94.36%. The application of the LVQ-NN on the test set allowed correct classification for 84.62% of the cases with CIN-2 or worse and 97.64% of the cases with CIN-1 or less, with overall accuracy of 96.03%. The use of the LVQ-NN with cytology and the proposed biomarkers improves significantly the correct classification of cervical precancerous lesions and/or cancer and may facilitate diagnosis and patient management.

show abstract

Alterations in human papillomavirus-related biomarkers after treatment of cervical intraepithelial neoplasia

Cited by 29 publications

References 21 publications

HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system

HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system

B-lymphocyte, Macrophage and Mast Cell Density in the Stroma Underlying HPV-Related Cervical Squamous Epithelial Lesions and their Relationship to Disease Severity: an Immunohistochemical Study

Identification of Women for Referral to Colposcopy by Neural Networks: A Preliminary Study Based on LBC and Molecular Biomarkers

Contact Info

Product

Resources

About